PMID- 17704995
OWN - NLM
STAT- MEDLINE
DCOM- 20071030
LR  - 20181201
IS  - 0914-8779 (Print)
IS  - 0914-8779 (Linking)
VI  - 25
IP  - 5
DP  - 2007
TI  - Factors affecting long-term compliance of osteoporotic patients with 
      bisphosphonate treatment and QOL assessment in actual practice: alendronate and 
      risedronate.
PG  - 302-9
AB  - The aim of our study was to examine compliance with a daily dose of 5 mg 
      alendronate (ALN) and 2.5 mg risedronate (RDN) in actual practice, and to 
      determine the causes of noncompliance through a questionnaire. In addition, we 
      studied the quality of life (QOL) of patients through another disease-related 
      questionnaire. The overall compliance rate remained at approximately 40% one year 
      after the initial dose. The rates did not differ significantly between the ALN 
      group (783 patients) and the RDN group (491 patients). The compliances in the 
      female group and the rheumatism group were better than in the male group and the 
      nonrheumatism group. From the questionnaire, 36% of noncompliant patients showed 
      adverse effects (AEs), and the other noncompliant patients stopped the medication 
      in spite of having no AEs. A logistic regression analysis of factors that might 
      have affected long-term compliance included AEs, an understanding of the disease, 
      the method of ingestion, visiting medical facilities, the shape of the tablet, 
      the cost of the drug, and the explanation of the doctor or pharmacist. This 
      analysis showed that noncompliance occurred mainly due to AEs, the inconvenience 
      of visiting a medical facility, unusual methods of ingestion, and a poor 
      understanding of the disease. According to the results of the questionnaire for 
      QOL assessment, the patients who continued the medication for more than 1 year 
      had improved scores for pain in both the ALN and RDN groups. Osteoporotic 
      treatment needs long-term patient compliance. To improve compliance, it is very 
      important that doctors and pharmacists ensure that patients understand the 
      purpose of this therapy.
FAU - Kamatari, Masayuki
AU  - Kamatari M
AD  - Maruzen Pharmacy, 3-3-23-104 Nishimikuni, Yodogawa-ku, Osaka 532-0006, Japan. 
      kama89314@yahoo.co.jp
FAU - Koto, Shiro
AU  - Koto S
FAU - Ozawa, Nobuhiro
AU  - Ozawa N
FAU - Urao, Chie
AU  - Urao C
FAU - Suzuki, Yumiko
AU  - Suzuki Y
FAU - Akasaka, Eri
AU  - Akasaka E
FAU - Yanagimoto, Kae
AU  - Yanagimoto K
FAU - Sakota, Kazumi
AU  - Sakota K
LA  - eng
PT  - Journal Article
DEP - 20070825
PL  - Japan
TA  - J Bone Miner Metab
JT  - Journal of bone and mineral metabolism
JID - 9436705
RN  - 0 (Diphosphonates)
RN  - KM2Z91756Z (Risedronic Acid)
RN  - M2F465ROXU (Etidronic Acid)
RN  - X1J18R4W8P (Alendronate)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Alendronate/administration & dosage/therapeutic use
MH  - Diphosphonates/administration & dosage/*therapeutic use
MH  - Etidronic Acid/administration & dosage/analogs & derivatives/therapeutic use
MH  - Female
MH  - Humans
MH  - Logistic Models
MH  - Male
MH  - Osteoporosis/*drug therapy/pathology
MH  - Patient Compliance/*statistics & numerical data
MH  - Quality of Life
MH  - Risedronic Acid
MH  - *Surveys and Questionnaires
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2007/08/21 09:00
MHDA- 2007/10/31 09:00
CRDT- 2007/08/21 09:00
PHST- 2006/09/13 00:00 [received]
PHST- 2007/04/02 00:00 [accepted]
PHST- 2007/08/21 09:00 [pubmed]
PHST- 2007/10/31 09:00 [medline]
PHST- 2007/08/21 09:00 [entrez]
AID - 10.1007/s00774-007-0768-6 [doi]
PST - ppublish
SO  - J Bone Miner Metab. 2007;25(5):302-9. doi: 10.1007/s00774-007-0768-6. Epub 2007 
      Aug 25.